Monocyte HLA-DR and Interferon-Gamma Treatment in Severely Injured Patients-A Critical Reappraisal More Than a Decade Later

Journal of the American College of Surgeons

Volumn 203, Issue 1, 2006, Pages 73-81

  Turina, Matthias ^a   Dickinson, Ashley ^a   Gardner, Sarah ^a   Polk Jr , Hiram C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MURAMYL DIPEPTIDE; PHOSPHORYL LIPID A; RECOMBINANT GAMMA INTERFERON;

ANTIGEN PRESENTING CELL; BACTERIAL INFECTION; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORRELATION ANALYSIS; CRITICALLY ILL PATIENT; DIARRHEA; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VITRO STUDY; INFECTION; INFECTION RISK; INJURY; LEUKOPENIA; MOLECULAR RECOGNITION; MONOCYTE; MORTALITY; NONHUMAN; POSTTRAUMATIC COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEPSIS; SURGICAL PATIENT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

CRITICAL ILLNESS; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; MONOCYTES; SURGICAL PROCEDURES, OPERATIVE; WOUNDS AND INJURIES;

EID: 33745201174     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2006.03.010     Document Type: Review

References (46)

1. Ashbaugh D.G., Bigelow D.B., Petty T.L., et al. Acute respiratory distress in adults. Lancet 2 (1967) 319-323
2. Fulton R.L., Rayner A.V., Jones C., et al. Analysis of factors leading to posttraumatic pulmonary insufficiency. Ann Thorac Surg 25 (1978) 500-509
3. McCloskey R.V., Straube R.C., Sanders C., et al., CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 121 (1994) 1-5
4. Rogy M.A., Moldawer L.L., Oldenburg H.S., et al. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI. Ann Surg 220 (1994) 77-85
5. Bone R.C., Balk R.A., Fein A.M., et al., The E5 Sepsis Study Group. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin. results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23 (1995) 994-1006
6. Greenman R.L., Schein R.M., Martin M.A., et al., The XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266 (1991) 1097-1102
7. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
8. Abraham E., Laterre P.F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 (2005) 1332-1341
9. Lowry S.F., Awad S., Ford H., et al. Static and dynamic assessment of biomarkers in surgical patients with severe sepsis. Surg Infect (Larchmt) 5 (2004) 261-268
10. Cheadle W.G., Wilson M., Hershman M.J., et al. Comparison of trauma assessment scores and their use in prediction of infection and death. Ann Surg 209 (1989) 541-545
11. Hershman M.J., Cheadle W.G., Wellhausen S.R., et al. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 77 (1990) 204-207
12. Hershman M.J., Polk Jr. H.C., Pietsch J.D., et al. Modulation of infection by gamma interferon treatment following trauma. Infect Immun 56 (1988) 2412-2416
13. Cheadle W.G. The human leukocyte antigens and their relationship to infection. Am J Surg 165 (1993) 75S-81S
14. Schinkel C., Sendtner R., Zimmer S., et al. Functional analysis of monocyte subsets in surgical sepsis. J Trauma 44 (1998) 743-748
15. Hershman M.J., Appel S.H., Wellhausen S.R., et al. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 77 (1989) 67-70
16. Tempero M.A., Sivinski C., Steplewski Z., et al. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer. biologic and clinical effects. J Clin Oncol 8 (1990) 2019-2026
17. Morimoto A., Murakami N., Takada M., et al. Fever and acute phase response induced in rabbits by human recombinant interferon-gamma. J Physiol 391 (1987) 209-218
18. Docke W.D., Hoflich C., Davis K.A., et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression. a multicenter standardized study. Clin Chem 51 (2005) 2341-2347
19. Pachot A., Monneret G., Brion A., et al. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 33 (2005) 31-38
20. Walsh D.S., Thavichaigarn P., Pattanapanyasat K., et al. Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury. J Surg Res 129 (2005) 221-230
21. Goldsby R.A., Kindt T.J., and Osborne B.A. Immunology (2003), WH Freeman and Company, New York
22. Bevan M.J. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. 1975. J Immunol 175 (2005) 7069-7084
23. Kuo E., Maruyama T., Fernandez F., et al. Molecular mechanisms of chronic rejection following transplantation. Immunol Res 32 (2005) 179-186
24. Seliger B., Ritz U., and Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118 (2006) 129-138
25. Polk Jr. H.C., George C.D., Wellhausen S.R., et al. A systematic study of host defense processes in badly injured patients. Ann Surg 204 (1986) 282-299
26. Livingston D.H., Appel S.H., Wellhausen S.R., et al. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 123 (1988) 1309-1312
27. Allen M.L., Peters M.J., Goldman A., et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med 30 (2002) 1140-1145
28. Ditschkowski M., Kreuzfelder E., Rebmann V., et al. HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 229 (1999) 246-254
29. Doecke W.D., Randow F., Syrbe U., et al. Monocyte deactivation in septic patients. restoration by IFN-gamma treatment. Nat Med 3 (1997) 678-681
30. Muller Kobold A.C., Tulleken J.E., Zijlstra J.G., et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 26 (2000) 883-892
31. Wakefield C.H., Carey P.D., Foulds S., et al. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 80 (1993) 205-209
32. Volk H.D., Reinke P., Krausch D., et al. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 Suppl 4 (1996) S474-S481
33. Schinkel C., Sendtner R., Zimmer S., et al. Evaluation of Fc-receptor positive (FcR+) and negative (FcR-) monocyte subsets in sepsis. Shock 11 (1999) 229-234
34. van den Berk J.M., Oldenburger R.H., van den Berg A.P., et al. Low HLA-DR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. Transplantation 63 (1997) 1846-1848
35. Asadullah K., Woiciechowsky C., Docke W.D., et al. Immunodepression following neurosurgical procedures. Crit Care Med 23 (1995) 1976-1983
36. Perry S.E., Mostafa S.M., Wenstone R., et al. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?. Intensive Care Med 29 (2003) 1245-1252
37. Oczenski W., Krenn H., Jilch R., et al. HLA-DR as a marker for increased risk for systemic inflammation and septic complications after cardiac surgery. Intensive Care Med 29 (2003) 1253-1257
38. Cheadle W.G., Hanasawa K., Gallinaro R.N., et al. Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis. Surgery 110 (1991) 785-791
39. Brown G.L., Foshee H., Pietsch J., et al. Muramyl dipeptide enhances survival from experimental peritonitis. Arch Surg 121 (1986) 47-49
40. Polk Jr. H.C., Cheadle W.G., Livingston D.H., et al. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 163 (1992) 191-196
41. Hershman M.J., Cheadle W.G., Kuftinec D., et al. An outcome predictive score for sepsis and death following injury. Injury 19 (1988) 263-266
42. Dries D.J., Jurkovich G.J., Maier R.V., et al. Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg 129 (1994) 1031-1041
43. Silverstein A.M. Cellular versus humoral immunology. a century-long dispute. Nat Immunol 4 (2003) 425-428
44. Shaw B. The doctor's dilemma (1954), Penguin Books, Baltimore
45. Schinkel C. The role of IFN-gamma in surgical patients. J Interferon Cytokine Res 23 (2003) 341-349
46. Turina M., Miller F.N., Tucker C.F., et al. Short-term hyperglycemia in surgical patients and a study of related cellular mechanisms. Ann Surg 243 (2006) 845-851